Analysts project a big spike in COPD market as new drugs arrive; Valeant raises $930M in latest asset sale
→ The COPD drug market is expected to grow dramatically over the next decade, hitting $14.1 billion by 2025, according to GlobalData. It was $9.9 billion in 2015. The growth will be fueled by increased diagnoses as well as new bronchodilator drug classes and anti-eosinophilic biologics.
→ Valeant is selling iNova for $930 million. The company is selling off assets in an attempt to reduce large piles of debt acquired under previous CEO Mike Pearson as he went on a deal-making spree. Pearson was replaced by Joseph Papa last year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.